Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy.  232 pts in 23 centers were enrolled over a 12 year period.  No differences were identified in the chemotherapy vs chemoradiotherapy groups for event-free survival (11.6 vs 12.8 mos) or median survival (26.2 vs 37.1).